I agree and would say $300mil is a fair valuation. GSK will probably take Silenor Over The Counter which could generate $100 mil in annual revenue. Sedor could sell for 3 X potential revs.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.